Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells

Archives of Pharmacal Research

Volumn 37, Issue 9, 2014, Pages 1234-1240

  Lee, Moonkyu ^a   Park, Chan Su ^a   Lee, Young Ran ^a   Im, Sun A ^a   Song, Sukgil ^a   Lee, Chong Kil ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Mammary carcinoma; Myeloid derived suppressor cell; R848; TLR7 8

Indexed keywords

RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; ANTINEOPLASTIC AGENT; DIFFERENTIATION ANTIGEN; IMIDAZOLE DERIVATIVE; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; MACROPHAGE; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHENOTYPE; SUPPRESSOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA; CELL CULTURE; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; GERMFREE ANIMAL; IMMUNOLOGY; METABOLISM; MYELOID PROGENITOR CELL; PATHOLOGY; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; IMIDAZOLES; IMMUNOLOGIC FACTORS; MACROPHAGES; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; MYELOID PROGENITOR CELLS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84906933858     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0379-4     Document Type: Article

References (31)

1. Almand, B., J.I. Clark, E. Nikitina, J. van Beynen, N.R. English, S.C. Knight, D.P. Carbone, and D.I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of Immunology 166: 678-689. (Pubitemid 32038493)
2. Assier, E., V. Marin-Esteban, A. Haziot, E. Maggi, D. Charron, and N. Mooney. 2007. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. Journal of Leukocyte Biology 81: 221-228. (Pubitemid 46021272)
3. Bunt, S.K., P. Sinha, V.K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology 176: 284-290. (Pubitemid 43023273)
4. Burns Jr, R.P., B. Ferbel, M. Tomai, R. Miller, and A.A. Gaspari. 2000. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clinical Immunology 94: 13-23. (Pubitemid 30026907)
5. Chuang, T.H., and R.J. Ulevitch. 2000. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. European Cytokine Network 11: 372-378. (Pubitemid 32268894)
6. Dockrell, D.H., and G.R. Kinghorn. 2001. Imiquimod and resiquimod as novel immunomodulators. Journal of Antimicrobial Chemotherapy 48: 751-755. (Pubitemid 33735309)
7. Gabrilovich, D.I., V. Bronte, S.H. Chen, M.P. Colombo, A. Ochoa, S. Ostrand-Rosenberg, and H. Schreiber. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Research 67: 425. (Pubitemid 46142802)
8. Gabrilovich, D.I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 9: 162-174.
9. Gabrilovich, D.I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology 12: 253-268.
10. Gorden, K.B., K.S. Gorski, S.J. Gibson, R.M. Kedl, W.C. Kieper, X. Qiu, M.A. Tomai, S.S. Alkan, and J.P. Vasilakos. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. The Journal of Clinical Immunology 174: 1259-1268.
11. Hackstein, H., A. Knoche, A. Nockher, J. Poeling, T. Kubin, M. Jurk, J. Vollmer, and G. Bein. 2011. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation. Cellular Immunology 271: 401-412.
12. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nature Immunology 5: 987-995. (Pubitemid 41057715)
13. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A.M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nature Immunology 3: 499. (Pubitemid 34669818)
14. Kanzler, H., F.J. Barrat, E.M. Hessel, and R.L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Medicine 13: 552-559. (Pubitemid 46830615)
15. Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research 63: 4441-4449. (Pubitemid 36951016)
16. Le, H.K., L. Graham, E. Cha, J.K. Morales, M.H. Manjili, and H.D. Bear. 2009. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumorbearing mice. International Immunopharmacology 9: 900-909.
17. Lee, J.K., M.K. Lee, Y.P. Yun, Y. Kim, J.S. Kim, Y.S. Kim, K. Kim, S.S. Han, and C.K. Lee. 2001. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. International Immunopharmacology 1: 1275-1284. (Pubitemid 32522981)
18. Lee, Y.R., Y.H. Lee, K.H. Kim, S.A. Im, and C.K. Lee. 2013. Induction of potent antigen-specific cytotoxic T cell response by PLGA-nanoparticles containing antigen and TLR agonist. Immune Network 13: 30-33.
19. Nagaraj, S., J.I. Youn, H. Weber, C. Iclozan, L. Lu, M.J. Cotter, C. Meyer, C.R. Becerra, M. Fishman, S. Antonia, M.B. Sporn, K.T. Liby, B. Rawal, J.H. Lee, and D.I. Gabrilovich. 2010. Antiinflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical Cancer Research 16: 1812-1823.
20. Ostrand-Rosenberg, S., P. Sinha, O. Chornoguz, and C. Ecker. 2012. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunology, Immunotherapy 61: 1319-1325.
21. Park, M.H., Y.J. Jung, and P.H. Kim. 2012. Newly identified TLR9 stimulant, M6-395, is a potent polyclonal activator for murine B cells. Immune Network 12: 27-32.
22. Rabinovich, G.A., D. Gabrilovich, and E.M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology 25: 267-296. (Pubitemid 46697910)
23. Serafini, P., I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology 16: 53-65. (Pubitemid 43139709)
24. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. The Journal of Clinical Investigation 117: 1155-1166. (Pubitemid 46718400)
25. Sinha, P., V.K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. Journal of Immunology 174: 636-645. (Pubitemid 40094255)
26. Stanley, M.A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clinical and Experimental Dermatology 27: 571-577. (Pubitemid 35463873)
27. Suzuki, E., V. Kapoor, A.S. Jassar, L.R. Kaiser, and S.M. Albelda. 2005. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research 11: 6713-6721. (Pubitemid 41339014)
28. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annual Review of Immunology 21: 335-376. (Pubitemid 37174535)
29. Thomsen, L.L., P. Topley, M.G. Daly, S.J. Brett, and J.P. Tite. 2004. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22: 1799-1809. (Pubitemid 38447228)
30. Vasilakos, J.P., and M.A. Tomai. 2013. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Review of Vaccines 12: 809-819.
31. Wiers, K.M., D.M. Lathers, M.A. Wright, and M.R. Young. 2000. Vitamin D3 treatment to diminish the levels of immune suppressive CD34? cells increases the effectiveness of adoptive immunotherapy. Journal of Immunotherapy 23: 115-124. (Pubitemid 30079832)